SHSE:603676 (China)
Â
Class A
Â¥
9.06
(+1%)
May 31
Business Description
Xizang Weixinkang Pharmaceutical Co Ltd
ISIN : CNE100002QQ3
Share Class Description:
SHSE:603676: Class ACompare
Compare
Traded in other countries / regions
603676.China IPO Date
2017-07-21Description
Xizang Weixinkang Pharmaceutical Co Ltd Formerly Tibet Weixinkang Medicine Co Ltd is a pharmaceutical company based in China. The company is engaged in the research and development, production and sales of the chemical drugs and their bulk drugs. Its core products cover the parenteral nutrition vitamins, electrolyte supplements, intravenous iron supplements, medicine for the digestive system and liver disease.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 155.82 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 417.14 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 7.3 | |||||
| Beneish M-Score | -2.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 21.7 | |||||
| 3-Year EBITDA Growth Rate | 50.1 | |||||
| 3-Year EPS without NRI Growth Rate | 61.6 | |||||
| 3-Year FCF Growth Rate | 28 | |||||
| 3-Year Book Growth Rate | 9.8 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.24 | |||||
| 9-Day RSI | 45.55 | |||||
| 14-Day RSI | 49.92 | |||||
| 6-1 Month Momentum % | -17.66 | |||||
| 12-1 Month Momentum % | -39.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.18 | |||||
| Quick Ratio | 3.1 | |||||
| Cash Ratio | 2.4 | |||||
| Days Inventory | 20.92 | |||||
| Days Sales Outstanding | 65.45 | |||||
| Days Payable | 148.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.62 | |||||
| Dividend Payout Ratio | 0.42 | |||||
| 3-Year Dividend Growth Rate | 73.5 | |||||
| Forward Dividend Yield % | 2.62 | |||||
| 5-Year Yield-on-Cost % | 9.95 | |||||
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 2.54 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.85 | |||||
| Operating Margin % | 11.25 | |||||
| Net Margin % | 19.28 | |||||
| FCF Margin % | 18.78 | |||||
| ROE % | 18.64 | |||||
| ROA % | 14.01 | |||||
| ROIC % | 25.02 | |||||
| ROC (Joel Greenblatt) % | 73.29 | |||||
| ROCE % | 18.69 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.62 | |||||
| PE Ratio without NRI | 16.18 | |||||
| Shiller PE Ratio | 1.46 | |||||
| Price-to-Owner-Earnings | 19.78 | |||||
| PEG Ratio | 0.56 | |||||
| PS Ratio | 2.99 | |||||
| PB Ratio | 2.75 | |||||
| Price-to-Tangible-Book | 2.86 | |||||
| Price-to-Free-Cash-Flow | 15.98 | |||||
| Price-to-Operating-Cash-Flow | 12.57 | |||||
| EV-to-EBIT | 11.49 | |||||
| EV-to-EBITDA | 11.49 | |||||
| EV-to-Revenue | 2.28 | |||||
| EV-to-FCF | 12.14 | |||||
| Price-to-Projected-FCF | 1.49 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.65 | |||||
| Price-to-Graham-Number | 1.43 | |||||
| Price-to-Net-Current-Asset-Value | 4.51 | |||||
| Price-to-Net-Cash | 7.25 | |||||
| Earnings Yield (Greenblatt) % | 8.7 | |||||
| FCF Yield % | 6.15 | |||||
| Forward Rate of Return (Yacktman) % | 23.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Xizang Weixinkang Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,290.108 | ||
| EPS (TTM) (Â¥) | 0.58 | ||
| Beta | 0.4 | ||
| Volatility % | 32.36 | ||
| 14-Day RSI | 49.92 | ||
| 14-Day ATR (Â¥) | 0.261082 | ||
| 20-Day SMA (Â¥) | 9.347 | ||
| 12-1 Month Momentum % | -39.43 | ||
| 52-Week Range (Â¥) | 6.3 - 14.59 | ||
| Shares Outstanding (Mil) | 435.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Xizang Weixinkang Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xizang Weixinkang Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Xizang Weixinkang Pharmaceutical Co Ltd Frequently Asked Questions
What is Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676)'s stock price today?
The current price of SHSE:603676 is ¥9.06. The 52 week high of SHSE:603676 is ¥14.59 and 52 week low is ¥6.30.
When is next earnings date of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676)?
The next earnings date of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) is .
Does Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) pay dividends? If so, how much?
The Dividend Yield %  of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) is 2.62% (As of Today), Highest Dividend Payout Ratio of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) was 0.67. The lowest was 0.42. And the median was 0.56. The  Forward Dividend Yield % of Xizang Weixinkang Pharmaceutical Co Ltd(SHSE:603676) is 2.62%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers